Little Summit Therapeutics spends big bucks to rebuild pipeline

$500 million upfront and a total deal value of up to $5 billion sounds like a deal made by a top-tier pharma company – but in fact it comes from diminutive biotech Summit Therapeutics.

The Anglo-US company – which ended its last financial quarter with cash and equivalents of less than $140 million – is financing the licensing deal for Chinese biotech Akeso’s PD-1 and VEGF-targeting bispecific antibody ivonescimab with debt and a $500 million rights offering due to take place early next year.

The debit facility is being provided by Summit’s co-chief executives Bob Duggan and Maky Zanganeh, both veterans of Pharmacyclics who pocketed rich rewards when the company was sold to AbbVie for $21 billion in 2015.

It’s been a torrid few years for Summit, which has seen two lead drug candidates – ezutromid for Duchenne muscular dystrophy and Clostridium difficile infection therapy ridinilazole –fail in mid- to late-stage clinical trials.

Ezutromid was abandoned in 2018 on phase 2 data, with Summit turning its attention ridinilazole only for the drug to miss the mark in a phase 3 study reported earlier this year, leaving the company with early-stage antibiotic and oncology projects.

With ivonescimab (AK112, and now also codenamed SMT112), Summit pivots further towards oncology, gaining US, Canada, Europe and Japan rights to a drug that has already advanced into clinical trials in China and Australia in multiple solid tumour types.

The drug is designed to combine PD-1 inhibition to remove a brake on the immune system as it fights cancer cells with blockade of VEGF, a growth factor that encourages the development of blood vessels that supply a tumour as it grows.

Akeso has taken the drug into a phase 3 study in patients with EGFR-positive non-small-cell lung cancer (NSCLC) that has progressed after treatment with an EGFR tyrosine kinase inhibitor (TKI), and Summit says it will start its own clinical programme in 2023.

In a phase 2 trial reported at this year’s ASCO congress, ivonescimab achieved a 68% overall response rate and almost doubled progression-free survival to more than eight months when added to standard chemotherapy in patients with this form of cancer.

The Chinese biotech has a track record in bispecific antibodies after cancer, having taken a PD-1/CTLA-4-targeting drug called cadonlimab through to regulatory approval in its home market as a treatment for relapsed or metastatic cervical cancer.

Duggan said the licensing deal is a “strategically compelling opportunity,” and that ivonescimab “has the potential for improving the quality and duration of patients’ lives.”

The post Little Summit Therapeutics spends big bucks to rebuild pipeline appeared first on .

therapeutics
antibodies
biotech
pharma